Targeted α-Particle Radiotherapy for Cancer

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Viewpoint is teaming with world-class companies and academic centers to bring its novel product line of therapeutics and complementary diagnostic imaging agents to personalized patient care for metastatic melanoma and neuroendocrine tumors.

Viewpoint Molecular Targeting™ Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U.S. Department of Energy Isotope Program

Coralville, IA, February 18, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into an agreement with the National Isotope Development Center (NIDC) for the long-term supply of parent feedstock radionuclide Th-228 for the manufacturing of the Company’s Ra-224/Pb-212 generator, VMT-𝛼-GEN.
READ MORE

Viewpoint Molecular Targeting™ Presents Positive Preclinical Data from VMT01 Program at the 2021 SNMMI Mid-Winter Meeting

Coralville, IA, February 1, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the presentation of positive preclinical data from its VMT01 program at the 2021 SNMMI Mid-Winter Meeting, which was held virtually January 28-31, 2021. READ MORE

Viewpoint Molecular Targeting™ to Present at the 2021 SNMMI Mid-Winter Meeting

Coralville, IA, January 27, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced its abstract has been selected for oral presentation at the 2021 SNMMI Mid-Winter Meeting, being held virtually January 28-31, 2021. READ MORE

Get in Touch

Join Our Mailing List

Enter your email address below for occasional updates from Viewpoint Molecular Targeting

©2021, Viewpoint Molecular Targeting™.  All Rights Reserved.